| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C-L Hou, M-Y Cai, X-R Ma, Y Zang, F-J Jia, Y-Q Lin, H F K Chiu, G S Ungvari, C H Ng, B-L Zhong, X-L Cao, Y Li, N Shinfuku, Y-T Xian. Clozapine prescription and quality of life in Chinese patients with schizophrenia treated in primary care. Pharmacopsychiatry. vol 48. issue 6. 2016-06-03. PMID:26244858. |
this study described the frequency, demographic and clinical characteristics of clozapine treatment and its impact on insight and quality of life (qol) of patients with schizophrenia treated in primary care in china. |
2016-06-03 |
2023-08-13 |
Not clear |
| Jimmy Lee, Hiroyoshi Takeuchi, Gagan Fervaha, Valerie Powell, Amaal Bhaloo, Robert Bies, Gary Remingto. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. Journal of clinical psychopharmacology. vol 35. issue 5. 2016-06-01. PMID:26267420. |
clozapine is the antipsychotic of choice for treatment-resistant schizophrenia and is linked to a need for mandatory hematological monitoring. |
2016-06-01 |
2023-08-13 |
Not clear |
| Venuja Sriretnakumar, Eric Huang, Daniel J Mülle. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert opinion on drug metabolism & toxicology. vol 11. issue 11. 2016-06-01. PMID:26364648. |
pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. |
2016-06-01 |
2023-08-13 |
Not clear |
| Venuja Sriretnakumar, Eric Huang, Daniel J Mülle. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert opinion on drug metabolism & toxicology. vol 11. issue 11. 2016-06-01. PMID:26364648. |
clozapine (clz) is the most effective treatment for treatment-resistant schizophrenia (scz) patients, with potential added benefits of reduction in suicide risk and aggression. |
2016-06-01 |
2023-08-13 |
Not clear |
| Zhengrong Liu, Wei Zheng, Shuai Gao, Zhisong Qin, Guannan Li, Yuping Nin. Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis. Shanghai archives of psychiatry. vol 27. issue 6. 2016-05-20. PMID:27199524. |
long-term use of clozapine for individuals with schizophrenia carries a high risk for developing metabolic abnormalities, especially clozapine-induced weight gain. |
2016-05-20 |
2023-08-13 |
Not clear |
| Mohamed Ahmed, Dara M Cannon, Cathy Scanlon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Peter McCarthy, Gareth J Barker, Brian Hallahan, Colm McDonal. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 10. 2016-05-09. PMID:25829144. |
progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. |
2016-05-09 |
2023-08-13 |
Not clear |
| Mohamed Ahmed, Dara M Cannon, Cathy Scanlon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Peter McCarthy, Gareth J Barker, Brian Hallahan, Colm McDonal. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 10. 2016-05-09. PMID:25829144. |
despite evidence that clozapine may be neuroprotective, there are few longitudinal magnetic resonance imaging (mri) studies that have specifically explored an association between commencement of clozapine treatment for schizophrenia and changes in regional brain volume or cortical thickness. |
2016-05-09 |
2023-08-13 |
Not clear |
| Mohamed Ahmed, Dara M Cannon, Cathy Scanlon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Peter McCarthy, Gareth J Barker, Brian Hallahan, Colm McDonal. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 10. 2016-05-09. PMID:25829144. |
a total of 33 patients with treatment-resistant schizophrenia and 31 healthy controls matched for age and gender underwent structural mri brain scans at baseline and 6-9 months after commencing clozapine. |
2016-05-09 |
2023-08-13 |
Not clear |
| Mohamed Ahmed, Dara M Cannon, Cathy Scanlon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Peter McCarthy, Gareth J Barker, Brian Hallahan, Colm McDonal. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 10. 2016-05-09. PMID:25829144. |
these findings demonstrate on-going reductions in brain volume and progressive cortical thinning in patients with schizophrenia who are switched to clozapine treatment. |
2016-05-09 |
2023-08-13 |
Not clear |
| Alp Üçok, Uğur Çikrikçili, Sercan Karabulut, Ada Salaj, Meliha Öztürk, Öznur Tabak, Rümeysa Dura. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International clinical psychopharmacology. vol 30. issue 5. 2016-05-02. PMID:26163875. |
delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. |
2016-05-02 |
2023-08-13 |
Not clear |
| Alp Üçok, Uğur Çikrikçili, Sercan Karabulut, Ada Salaj, Meliha Öztürk, Öznur Tabak, Rümeysa Dura. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International clinical psychopharmacology. vol 30. issue 5. 2016-05-02. PMID:26163875. |
the aim of this retrospective chart-review study was to investigate the relationship between delayed commencement of clozapine and the level of response in treatment-resistant schizophrenia (trs). |
2016-05-02 |
2023-08-13 |
Not clear |
| Alp Üçok, Uğur Çikrikçili, Sercan Karabulut, Ada Salaj, Meliha Öztürk, Öznur Tabak, Rümeysa Dura. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International clinical psychopharmacology. vol 30. issue 5. 2016-05-02. PMID:26163875. |
we included 162 patients with schizophrenia who used clozapine. |
2016-05-02 |
2023-08-13 |
Not clear |
| Kristina Melkersson, Moira Lewitt, Kerstin Hal. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro endocrinology letters. vol 36. issue 5. 2016-04-21. PMID:26707048. |
higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. |
2016-04-21 |
2023-08-13 |
Not clear |
| Kristina Melkersson, Moira Lewitt, Kerstin Hal. Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro endocrinology letters. vol 36. issue 5. 2016-04-21. PMID:26707048. |
the effect of long-term treatment with the atypical antipsychotic clozapine on the serum amino acid profile in schizophrenia patients has not previously been studied. |
2016-04-21 |
2023-08-13 |
Not clear |
| Jimmy Lee, Gagan Fervaha, Hiroyoshi Takeuchi, Valerie Powell, Gary Remingto. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. Journal of clinical psychopharmacology. vol 35. issue 3. 2016-04-19. PMID:25839337. |
participants were patients with a diagnosis of schizophrenia or schizoaffective disorder who failed 2 prior antipsychotic trials and were considered candidates for clozapine. |
2016-04-19 |
2023-08-13 |
human |
| Valentina Bruno, Alicia Valiente-Gómez, Oscar Alcoverr. Clozapine and Fever: A Case of Continued Therapy With Clozapine. Clinical neuropharmacology. vol 38. issue 4. 2016-04-11. PMID:26166236. |
clozapine is a major atypical antipsychotic drug used in treatment-resistant schizophrenia (patel and allin. |
2016-04-11 |
2023-08-13 |
Not clear |
| Elena Clare Vowels, Shashidhara Hittur Lingappa, Tarun Bastiampilla. Combination clozapine and electroconvulsive therapy in a patient with schizophrenia and comorbid intellectual disability. The Australian and New Zealand journal of psychiatry. vol 48. issue 7. 2016-04-08. PMID:24567541. |
combination clozapine and electroconvulsive therapy in a patient with schizophrenia and comorbid intellectual disability. |
2016-04-08 |
2023-08-12 |
Not clear |
| Yun-Jung Cho. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. TheScientificWorldJournal. vol 2015. 2016-04-08. PMID:25664341. |
efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. |
2016-04-08 |
2023-08-13 |
Not clear |
| A-N Li, F Dong, J-L He, D-W Shang, W Guo, W-B Li, W Lu, C-Y Wan. The Elimination Rate after Clozapine Overdose in Chinese Schizophrenia Patients: A Population Pharmacokinetics Model Study. Pharmacopsychiatry. vol 48. issue 4-5. 2016-04-07. PMID:26079968. |
the elimination rate after clozapine overdose in chinese schizophrenia patients: a population pharmacokinetics model study. |
2016-04-07 |
2023-08-13 |
Not clear |
| T Forrester, D Siskind, K Winckel, A Wheeler, S Hollingwort. Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013. Pharmacopsychiatry. vol 48. issue 4-5. 2016-04-07. PMID:26091280. |
clozapine is the most effective treatment for treatment-resistant schizophrenia but its use is suboptimal. |
2016-04-07 |
2023-08-13 |
Not clear |